The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 10, 2022

Filed:

Feb. 10, 2017
Applicant:

Bluebird Bio, Inc., Cambridge, MA (US);

Inventors:

Melissa Bonner, Natick, MA (US);

Olivier Negre, Cambridge, MA (US);

Christopher Tipper, Cambridge, MA (US);

Assignee:

bluebird bio, Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/867 (2006.01); A61K 35/28 (2015.01); C12N 5/0789 (2010.01); A61K 31/557 (2006.01); C12N 5/16 (2006.01); C12N 15/85 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/867 (2013.01); A61K 31/557 (2013.01); A61K 35/28 (2013.01); C12N 5/0647 (2013.01); C12N 5/16 (2013.01); C12N 15/85 (2013.01); A61K 48/00 (2013.01); C12N 2501/392 (2013.01); C12N 2501/999 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/16043 (2013.01);
Abstract

The invention provides improved gene therapy methods and compositions. In particular embodiments, gene therapies comprise hematopoietic stem and progenitor cell compositions with increased therapeutic efficacy and methods of making and using the same. In other particular embodiments, the present invention contemplates compositions and methods for increasing transduction efficiency and vector copy number (VCN) of human hematopoietic stem and progenitor cells (HSPCs) to yield improved gene therapy compositions. In various embodiments, the present invention contemplates, in part, a population of HSPCs transduced with a lentiviral vector. In various embodiments, the present invention contemplates a method of treating sickle cell disease in a subject comprising administering the subject an effective amount of the population of hematopoietic cells contemplated herein. In various embodiments, the present invention contemplates a kit comprising an agent that increases prostaglandin EP receptor signaling and staurosporine.


Find Patent Forward Citations

Loading…